Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

Next Previous
X
Search
Trial Profile

Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept
  • Acronyms CLEAR MIND
  • Sponsors Longeveron

    • Most Recent Events

    • 14 Aug 2024 According to a Longeveron media release, the reduced cost of supplies of $0.4 and $0.1 MM of lower equity-based compensation expenses allocated to R & D expenses. These reductions were partially offset by $0.6 MM of higher compensation and benefit costs.
    • 14 Aug 2024 According to a Longeveron media release, R &D expenses for the 6 months ended Jun 30, 2024 decreased to approx. $3.9 MM from approx. $5.1 MM for the same period in 2023. The decrease of $1.2 MM, or 22%, was primarily due to a decrease of $1.3 MM in R & D expenses being incurred for this trial and reduced costs for the aging-related frailty clinical trial following decision to discontinue trial activities in Japan.
    • 28 Jul 2024 According to a Longeveron media release, company is looking forward to meeting the FDA to review this data and discuss the future development path for Lomecel-B™ in Alzheimer's Disease.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top